Related Experiment Video
Updated: Feb 11, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib
Ichiro Sakanoue1, Hiroshi Hamakawa1, Reiko Kaji2
1Department of Thoracic Surgery, Kobe City Medical Center General Hospital, Kobe, Japan.
Abstract:
Afatinib, the second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has been postulated to be associated with improved inhibition of EGFR-dependent tumor growth compared with first-generation EGFR-TKIs for advanced non-small cell lung cancer (NSCLC). We present a case of lung adenocarcinoma (cT3N0M0) treated with neoadjuvant afatinib and sleeve lobectomy. Because of the location of the tumor, reduced FEV1 value, and the presence of EGFR mutation, the patient was planned to be prescribed afatinib (30 mg daily) for 3 weeks as neoadjuvant therapy and underwent sleeve lobectomy to avoid pneumonectomy as much as possible. Although the patient presented with grade 3 diarrhea and dose reduction of afatinib to 20 mg daily was needed, several image findings showed a partial response of the tumor on Day 20. Oral administration of afatinib was discontinued on Day 22. A right upper sleeve lobectomy combined with partial resection of lower lobe was performed after oral administration of afatinib on Day 24. The patient's postoperative course was uneventful and she has been free of recurrence for 26 months. This strategy could reduce the risk of pneumonectomy with acceptable side effects. The treatment, clinical course and pathological findings of the patient are discussed.
Insights
Neoadjuvant afatinib therapy in non-small cell lung cancer (NSCLC) showed partial tumor response, enabling lung-sparing sleeve lobectomy. This approach reduced pneumonectomy risk with manageable side effects, achieving 26-month recurrence-free survival.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced non-small cell lung cancer (NSCLC) treatment often involves epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).
- Second-generation EGFR-TKIs like afatinib may offer improved efficacy over first-generation agents.
- Neoadjuvant therapy aims to shrink tumors, potentially allowing less invasive surgical procedures.
Observation:
- A case study of a lung adenocarcinoma patient (cT3N0M0) with reduced FEV1 and EGFR mutation.
- Neoadjuvant afatinib (30 mg daily) was administered for 3 weeks prior to sleeve lobectomy.
- The patient experienced grade 3 diarrhea, necessitating a dose reduction to 20 mg daily.
Findings:
- Imaging revealed a partial response of the tumor by Day 20 of afatinib treatment.
- Afatinib was discontinued on Day 22, followed by a sleeve lobectomy on Day 24.
- The patient experienced an uneventful postoperative recovery and remained recurrence-free for 26 months.
Implications:
- Neoadjuvant afatinib can facilitate lung-sparing surgery (sleeve lobectomy) in select NSCLC patients.
- This strategy may reduce the need for pneumonectomy, preserving lung function.
- Managing side effects like diarrhea is crucial for successful neoadjuvant TKI therapy.
More Related Videos
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
Related Concept Videos
Lung Capacity
Pleura of the Lungs
Gross Anatomy of the Lungs
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Breathing
Gas Exchange and Transport